Actinium Names Five to Scientific Advisory Board
The clinicians and scientists will guide development of the company's targeted radiotherapy pipeline across solid tumor and hematologic cancer programs.
Updated on Nov. 9, 2026 in Cancer

Actinium Pharmaceuticals has named five clinicians and scientists to a scientific advisory board. The board will guide development of the company's targeted radiotherapy pipeline, including ATNM-400, a HER3-targeted alpha radiotherapy in a first-in-human phase I study in metastatic castration-resistant prostate cancer.
Why it matters
The appointments add senior clinical and scientific oversight to targeted alpha radiotherapy development, a field pursuing treatments for hard-to-treat cancers. The board's input on trial design and patient selection could shape how the programs advance toward later-stage testing.
The announcement reports five appointees, a figure without a stated comparator in the release. Terms of engagement, compensation and advisory timelines were not disclosed.
The players
Actinium Pharmaceuticals
Actinium Pharmaceuticals is a company developing targeted radiotherapies for cancer, including its HER3-targeted alpha radiotherapy ATNM-400.
Karim Fizazi
Karim Fizazi is director general of the Centre Oscar Lambret in Lille, France, a cancer center with a research and clinical focus on oncology.
Sergio Giralt
Sergio Giralt is deputy division head of hematologic malignancies at Memorial Sloan Kettering Cancer Center, a leading U.S. cancer research institution.
Michael Morris
Michael Morris is prostate cancer section head at Memorial Sloan Kettering Cancer Center, where he works on prostate cancer clinical care and research.
Jason Lewis
Jason Lewis is scientific director of the radiochemistry and molecular imaging probe core facility at Memorial Sloan Kettering Cancer Center, specializing in radiopharmaceutical imaging.
The details
The advisory board includes Karim Fizazi, director general of the Centre Oscar Lambret in Lille, France; Sergio Giralt of Memorial Sloan Kettering Cancer Center; Jason Lewis, scientific director of the radiochemistry and molecular imaging probe core facility at Memorial Sloan Kettering; and Michael Morris, prostate cancer section head at Memorial Sloan Kettering. The board will advise on clinical development strategy, trial design, patient selection, molecular imaging and therapeutic combinations across Actinium's solid tumor and hematologic cancer programs.
Big Picture
Actinium's HER3-targeted alpha radiotherapy ATNM-400 is in phase I testing for metastatic castration-resistant prostate cancer, placing the new board at an early stage of clinical development for alpha-emitting therapies. The appointments add expert guidance as the program works toward defining patient selection and trial design.
For patients with advanced prostate cancer, early-phase trials of new radiotherapies may eventually broaden treatment options, though ATNM-400 remains in first-in-human testing. The appointments do not yet change available care or access to the therapy.
The takeaway
Advisory boards with clinical trial expertise can shape how early-stage cancer therapies are tested and selected for patients. Readers following cancer drug development can watch for phase I results before drawing conclusions about efficacy.
Further reading
Explore more on Cancer research and treatment developments.







